TheEdgeResearch
Home / Stocks / ARVN

Arvinas, Inc. (ARVN)

NASDAQ Healthcare Biotechnology
$6.46 ▼ -4.15%
Market Cap
$423.0M
Sector
Healthcare
Industry
Biotechnology
Beta
1.80
52-Wk Range
6.33-14.51
CEO
Randy Teel
Country
US
Currency
USD

Arvinas, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New Haven, CT, US. The stock last traded at $6.46, down 4.15% on the session, giving a market capitalisation of $423.0M. On trailing twelve-month figures it carries a trailing P/E of -43.07, a net margin of -3.5%. Its beta of 1.80 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-43.07
Price / Sales
1.54
Price / Book
0.82
EV / EBITDA
-15.79
Gross margin
95.9%
Operating margin
-10.7%
Net margin
-3.5%
Return on equity
—
Debt / equity
0.01
Current ratio
8.39
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
246
IPO date
2018-09-27
Headquarters
New Haven, CT, US
About Arvinas, Inc.

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

Comparable companies

Arvinas, Inc. is most often compared with the following Healthcare names:

CCCCFHTXGLUEKYMRNRIX
More research on ARVN
ARVN technical analysis ARVN TheEdge Score Compare against peers
Open full interactive analysis & DCF →